Pharmaceutical Technology on MSN

JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success

The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well ...
News Medical

New Technique to Monitor DNA Release and Capsid Protein Stability

Watch this dynamic webinar for valuable insights into characterizing the stability of an engineered adeno-associated virus (AAV) serotype under moderate thermal stress and physiological solution ...

Avista Therapeutics Expands AI Gene Therapy Platform to Break Barriers in the Delivery of Genetic Medicines

Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, today announced the significant expansion of its gene therapy platform.
BioTechniques

Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV

High-quality HIV antigens for cutting-edge solutions. On February 18, 2025, Gilead Sciences (CA, US) announced a significant milestone: the US FDA accepted their New Drug Applications (NDAs) for ...
GEN

Conquering the Complexities of AAV Manufacturing: Advances in Efficiency, Scalability, Compliance

Adeno-associated viruses (AAV) have emerged as pivotal delivery vehicles for gene therapy due to their overall safety (less immunogenic), efficiency (broad tropism), and long-term gene expression.